These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 31664773)
1. Identification of IDH and TERTp mutation status using Ozturk-Isik E; Cengiz S; Ozcan A; Yakicier C; Ersen Danyeli A; Pamir MN; Özduman K; Dincer A J Magn Reson Imaging; 2020 Jun; 51(6):1799-1809. PubMed ID: 31664773 [TBL] [Abstract][Full Text] [Related]
2. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
3. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
4. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients. Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731 [TBL] [Abstract][Full Text] [Related]
5. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study. Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938 [TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880 [TBL] [Abstract][Full Text] [Related]
7. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427 [TBL] [Abstract][Full Text] [Related]
8. Identification of IDH and TERTp mutations using dynamic susceptibility contrast MRI with deep learning in 162 gliomas. Buz-Yalug B; Turhan G; Cetin AI; Dindar SS; Danyeli AE; Yakicier C; Pamir MN; Özduman K; Dincer A; Ozturk-Isik E Eur J Radiol; 2024 Jan; 170():111257. PubMed ID: 38134710 [TBL] [Abstract][Full Text] [Related]
9. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770 [TBL] [Abstract][Full Text] [Related]
10. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T; Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363 [TBL] [Abstract][Full Text] [Related]
11. Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines. Bai H; Bai S; Li X; Zhang Y; Li Y; He F; Cheng W Biomed Res Int; 2021; 2021():3271395. PubMed ID: 34159191 [TBL] [Abstract][Full Text] [Related]
12. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624 [TBL] [Abstract][Full Text] [Related]
13. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589 [TBL] [Abstract][Full Text] [Related]
14. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040 [TBL] [Abstract][Full Text] [Related]
15. IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas. Duan WC; Wang L; Li K; Wang WW; Zhan YB; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZY Medicine (Baltimore); 2018 Dec; 97(50):e13675. PubMed ID: 30558073 [TBL] [Abstract][Full Text] [Related]
16. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI. Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279 [TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060 [TBL] [Abstract][Full Text] [Related]
18. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study. Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076 [TBL] [Abstract][Full Text] [Related]
19. In vivo Metabolic Profiles as Determined by Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683 [TBL] [Abstract][Full Text] [Related]
20. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]